A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POTEYK-SLE-1)

Brief description of study

Researchers hope to learn more about whether deucravacitinib can help in the treatment of SLE and how safe it is to use in people with SLE. Deucravacitinib is an experimental drug, which means its safety and effectiveness have not been established and it is not approved by the FDA. Placebo looks like the study drug but does not contain active treatment.

Clinical Study Identifier: s22-01179
ClinicalTrials.gov Identifier: NCT05617677
Principal Investigator: Amit Saxena.
Other Investigator: Janine M. Sullivan.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.